Aeglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes which have been engineered to have optimized catalytic and biopharmaceutic properties. The metabolic basis of tumor amino acid dependence is fundamentally different from the nutritional needs of normal tissues, creating a vulnerability to selective killing of tumor cells. Aeglea’s first two programs utilize enzymes that degrade either the amino acid L-methionine (Met) or L-arginine (Arg) for use as therapy in oncology. The Company's therapeutic strategy takes advantage of decades of clinical validation to leverage the genetic and epigenetic basis of tumor AA auxotrophy to identify patients likely to benefit from these molecules.
TypePublic
HQAustin, US
Founded2013
Size (employees)45 (est)+19%
Websiteaegleabio.com
Aeglea Biotherapeutics was founded in 2013 and is headquartered in Austin, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Aeglea Biotherapeutics

M.B Anthony Quinn

M.B Anthony Quinn

President & Chief Executive Officer
James Wooldridge

James Wooldridge

Chief Medical Officer
Charles N. York

Charles N. York

CFO
Aaron Schuchart

Aaron Schuchart

Chief Business Officer
Scott W. Rowlinson

Scott W. Rowlinson

Vice President of Research
Leslie Sloan

Leslie Sloan

Senior Vice President of Operations
Show more

Aeglea Biotherapeutics Office Locations

Aeglea Biotherapeutics has an office in Austin
Austin, US (HQ)
250 Barton Oaks Plaza One 901 S MoPac Expy
Show all (1)
Report incorrect company information

Aeglea Biotherapeutics Financials and Metrics

Aeglea Biotherapeutics Revenue

USD

Net income (Q2, 2018)

(17.5m)

EBIT (Q2, 2018)

(17.9m)

Market capitalization (11-Oct-2018)

199.5m

Closing stock price (11-Oct-2018)

9.1

Cash (30-Jun-2018)

20.6m
Aeglea Biotherapeutics's current market capitalization is $199.5 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

8.4m10.1m

R&D expense

18.1m22.8m

Operating expense total

26.5m32.9m

EBIT

(21.9m)(27.7m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

General and administrative expense

1.8m2.4m2.1m2.4m2.4m2.9m5.8m

R&D expense

3.6m4.4m5.4m4.9m5.8m6.9m16.0m

Operating expense total

5.4m6.9m7.5m7.3m8.2m9.8m21.8m

EBIT

(4.6m)(5.5m)(6.3m)(6.3m)(6.7m)(8.2m)(17.9m)
Annual
USDFY, 2016FY, 2017

Cash

47.7m12.8m

Accounts Receivable

164.2m

Inventories

1.7m

Current Assets

66.4m55.0m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

24.0m70.6m49.5m16.8m26.9m10.8m20.6m

Current Assets

35.2m76.9m71.7m60.3m66.2m48.8m78.9m

PP&E

321.0k377.0k342.0k822.0k802.0k810.0k776.0k

Total Assets

35.5m77.3m72.1m61.3m67.1m49.8m79.7m
Annual
USDFY, 2016FY, 2017

Net Income

(21.7m)(27.2m)

Depreciation and Amortization

132.0k249.0k

Inventories

(96.1k)

Accounts Payable

(8.0k)164.0k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(4.5m)(5.4m)(6.2m)(6.2m)(8.1m)(17.5m)

Depreciation and Amortization

70.0k145.0k

Accounts Payable

509.0k348.0k523.0k267.0k396.0k579.0k

Cash From Operating Activities

(7.4m)(16.5m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Aeglea Biotherapeutics Operating Metrics

FY, 2016

Nonclinical Development

3

Phase 1/2 Trials Products

1

Phase Approved

1

Phase I Trials Products

2
Show all operating metrics
Report incorrect company information

Aeglea Biotherapeutics Blogs

Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting

Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting Content Import Wed, 10/10/2018 - 08:04 Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual M…

FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency

Aeglea Eligible to Receive a Priority Review Voucher Company Plans to Initiate Pivotal Trial in First Half of 2019 AUSTIN, Texas , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme

Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology

AUSTIN, Texas , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will deliver an oral

Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer

Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer Content Import Thu, 07/19/2018 - 16:02 Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer 07/19/18 This release is a backfi…

Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors

Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors Content Import Mon, 07/16/2018 - 08:04 Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors 07/16/18 This release is a backfill from a News Wire General …

Aeglea Biotherapeutics Company Life and Culture

Report incorrect company information